Toby Greenfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toby Greenfield has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- James Robert Bonham
Sheffield Children’s NHS Foundation Trust, Sheffield S10 2TH, UK
2 shared publications - Nazia Taj
Clinical Biochemistry, Oxford University Hospitals NHS(FT), Oxford OX9 3DU, UK
2 shared publications - Tejswurree Ramgoolam
Department of Chemical Pathology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK
2 shared publications - Beverly Hird
Clinical Biochemistry, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK
1 shared publication - Caroline Griffith
Specialist Laboratory Medicine, Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds LS9 7TF, UK
1 shared publication - Catherine Collingwood
Biochemistry Department, Alder Hey Children’s NHS Foundation Trust, Liverpool L12 2AP, UK
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 41
Transitioning from Laboratory-Developed Tests to a Single Commercial Reagent Kit in a National Newborn Screening Program: Impact on Analytical Performance and Harmonization
Newborn screening in England is a national program with laboratories adhering to common screening algorithms. Until recently, screening for inherited metabolic disorders was provided by ten laboratories using laboratory-developed tests (LDTs) and three using commercial assays: harmonization of results proved challenging. Introduction of hereditary tyrosinemia type 1 screening meant LDTs required modification to include the measurement of succinylacetone, and subsequent re-validation. This provided an opportunity to implement a single commercial reagent kit in all laboratories. It was anticipated that this would improve analytical performance and harmonization. This study aimed to determine whether these goals were achieved. Verification across the 13 laboratories revealed that the commercial kit reduced inter-laboratory variation for all analytes demonstrating improved harmonization. However, this was achieved by applying instrument-specific correction factors to all analytes, the magnitude of which were significant, indicating a lack of standardization. Performance of succinylacetone was limited by instrument-dependent background interference from the methionine stable isotope label, underscoring the need to establish evidence-based screening cut-off values (COV) rather than adopting published thresholds. This study emphasizes the need for traceable reference materials to improve laboratory quality and the value of screening outcome data.
- 9 June 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 41
Open AccessTransitioning from Laboratory-Developed Tests to a Single Commercial Reagent Kit in a National Newborn Screening Program: Impact on Analytical Performance and Harmonization
Newborn screening in England is a national program with laboratories adhering to common screening algorithms. Until recently, screening for inherited metabolic disorders was provided by ten laboratories using laboratory-developed tests (LDTs) and three using commercial assays: harmonization of results proved challenging. Introduction of hereditary tyrosinemia type 1 screening meant LDTs required modification to include the measurement of succinylacetone, and subsequent re-validation. This provided an opportunity to implement a single commercial reagent kit in all laboratories. It was anticipated that this would improve analytical performance and harmonization. This study aimed to determine whether these goals were achieved. Verification across the 13 laboratories revealed that the commercial kit reduced inter-laboratory variation for all analytes demonstrating improved harmonization. However, this was achieved by applying instrument-specific correction factors to all analytes, the magnitude of which were significant, indicating a lack of standardization. Performance of succinylacetone was limited by instrument-dependent background interference from the methionine stable isotope label, underscoring the need to establish evidence-based screening cut-off values (COV) rather than adopting published thresholds. This study emphasizes the need for traceable reference materials to improve laboratory quality and the value of screening outcome data.
- Open Access
- 28 April 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 28
The Variation in IRT in Different Ethnic Groups in England—Implications for a Newborn Screening Programme for CF in Diverse Multiethnic Populations
Increasing ethnic diversity raises potential inequalities within screening programmes. In the UK, newborns are screened for CF by initially measuring IRT. Dried blood spot IRT levels above a set cut-off require follow-up testing to establish a screening result. Variation exists in IRT levels between different ethnicities and therefore impacts the number of potentially false positive results obtained from ethnic groups. Over a 4-year period, IRT data was collected, and the 99.5th centile was calculated for different ethnic groups. Significant differences were noticed between ethnic groups, and the CF outcome data over a 10-year period were then analysed to establish the effect this had on positive predictive values. The largest difference in IRT 99.5th centile values was seen between the White British and Black African groups. Positive predictive values for Black African and Indian ethnic groups were much lower than the other groups. Rather than try to incorporate ethnicity into the UK CF screening algorithm, we suggest making CF clinicians aware of the differences between different ethnic groups to inform counselling families who receive screen-positive results.
- 28 April 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 28
Open AccessThe Variation in IRT in Different Ethnic Groups in England—Implications for a Newborn Screening Programme for CF in Diverse Multiethnic Populations
Increasing ethnic diversity raises potential inequalities within screening programmes. In the UK, newborns are screened for CF by initially measuring IRT. Dried blood spot IRT levels above a set cut-off require follow-up testing to establish a screening result. Variation exists in IRT levels between different ethnicities and therefore impacts the number of potentially false positive results obtained from ethnic groups. Over a 4-year period, IRT data was collected, and the 99.5th centile was calculated for different ethnic groups. Significant differences were noticed between ethnic groups, and the CF outcome data over a 10-year period were then analysed to establish the effect this had on positive predictive values. The largest difference in IRT 99.5th centile values was seen between the White British and Black African groups. Positive predictive values for Black African and Indian ethnic groups were much lower than the other groups. Rather than try to incorporate ethnicity into the UK CF screening algorithm, we suggest making CF clinicians aware of the differences between different ethnic groups to inform counselling families who receive screen-positive results.